請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32025完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳青周(Ching-Chow Chen) | |
| dc.contributor.author | Wei-Lun Chen | en |
| dc.contributor.author | 陳韋綸 | zh_TW |
| dc.date.accessioned | 2021-06-13T03:28:30Z | - |
| dc.date.available | 2009-08-02 | |
| dc.date.copyright | 2006-08-02 | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006-07-28 | |
| dc.identifier.citation | Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A and Ben-Neriah Y (1995) Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 92:10599-10603.
Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD and Baldwin AS (2003) A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 423:659-663. Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE and Schafer H (2001) Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20:859-868. Auphan N, DiDonato JA, Rosette C, Helmberg A and Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290. Baeuerle PA (1998) IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 95:729-731. Baeuerle PA and Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141-179. Baldwin AS, Jr. (2001) Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107:3-6. Balkwill F and Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545. Battistutta R, Sarno S, De Moliner E, Papinutto E, Zanotti G and Pinna LA (2000) The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem 275:29618-29622. Beg AA, Sha WC, Bronson RT, Ghosh S and Baltimore D (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376:167-170. Bender K, Gottlicher M, Whiteside S, Rahmsdorf HJ and Herrlich P (1998) Sequential DNA damage-independent and -dependent activation of NF-kappaB by UV. Embo J 17:5170-5181. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP and Bours V (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22:90-97. Beraud C, Henzel WJ and Baeuerle PA (1999) Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci U S A 96:429-434. Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430:257-263. Booy EP, Johar D, Maddika S, Pirzada H, Sahib MM, Gehrke I, Loewen S, Louis SF, Kadkhoda K, Mowat M and Los M (2006) Monoclonal and bispecific antibodies as novel therapeutics. Arch Immunol Ther Exp (Warsz) 54:85-101. Bork PM, Schmitz ML, Kuhnt M, Escher C and Heinrich M (1997) Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 402:85-90. Bottero V, Busuttil V, Loubat A, Magne N, Fischel JL, Milano G and Peyron JF (2001) Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 61:7785-7791. Bourgarel-Rey V, Vallee S, Rimet O, Champion S, Braguer D, Desobry A, Briand C and Barra Y (2001) Involvement of nuclear factor kappaB in c-Myc induction by tubulin polymerization inhibitors. Mol Pharmacol 59:1165-1170. Brown K, Gerstberger S, Carlson L, Franzoso G and Siebenlist U (1995) Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485-1488. Burke F, Relf M, Negus R and Balkwill F (1996) A cytokine profile of normal and malignant ovary. Cytokine 8:578-585. Chang YJ, Wu MS, Lin JT and Chen CC (2005) Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 175:8242-8252. Chang YJ, Wu MS, Lin JT, Pestell RG, Blaser MJ and Chen CC (2006) Mechanisms for Helicobacter pylori CagA-induced cyclin D1 expression that affect cell cycle. Cell Microbiol. Chen C, Chou C, Sun Y and Huang W (2001a) Tumor necrosis factor alpha-induced activation of downstream NF-kappaB site of the promoter mediates epithelial ICAM-1 expression and monocyte adhesion. Involvement of PKCalpha, tyrosine kinase, and IKK2, but not MAPKs, pathway. Cell Signal 13:543-553. Chen CC, Chen JJ and Chou CY (2000a) Protein kinase calpha but not p44/42 mitogen-activated protein kinase, p38, or c-Jun NH(2)-terminal kinase is required for intercellular adhesion molecule-1 expression mediated by interleukin-1beta: involvement of sequential activation of tyrosine kinase, nuclear factor-kappaB-inducing kinase, and IkappaB kinase 2. Mol Pharmacol 58:1479-1489. Chen CC, Chiu KT, Chan ST and Chern JW (2001b) Conjugated polyhydroxybenzene derivatives block tumor necrosis factor-alpha-mediated nuclear factor-kappaB activation and cyclooxygenase-2 gene transcription by targeting IkappaB kinase activity. Mol Pharmacol 60:1439-1448. Chen CC, Sun YT, Chen JJ and Chiu KT (2000b) TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway. J Immunol 165:2719-2728. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D and Maniatis T (1995) Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9:1586-1597. Cohen L, Henzel WJ and Baeuerle PA (1998) IKAP is a scaffold protein of the IkappaB kinase complex. Nature 395:292-296. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM and Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935-942. Coiffier B (2002) Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 29:18-22. Coussens LM and Werb Z (2002) Inflammation and cancer. Nature 420:860-867. Cramer P and Muller CW (1999) A firm hand on NFkappaB: structures of the IkappaBalpha-NFkappaB complex. Structure 7:R1-6. Cusack JC, Jr., Liu R, Houston M, Abendroth K, Elliott PJ, Adams J and Baldwin AS, Jr. (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535-3540. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF and Green DR (2002) The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17:525-535. Dhala A, Pinsker K and Prezant DJ (2004) Respiratory health consequences of environmental tobacco smoke. Med Clin North Am 88:1535-1552, xi. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E and Karin M (1997) A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388:548-554. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, Lipsky JJ and McKean DJ (1999) Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 274:26448-26453. Ekbom A (1998) Risk of cancer in ulcerative colitis. J Gastrointest Surg 2:312-313. Fosslien E (2000) Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37:431-502. Garg A and Aggarwal BB (2002) Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16:1053-1068. Ghosh S and Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl:S81-96. Ghosh S, May MJ and Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70. Hehner SP, Hofmann TG, Droge W and Schmitz ML (1999) The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 163:5617-5623. Henkel T, Zabel U, van Zee K, Muller JM, Fanning E and Baeuerle PA (1992) Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-kappa B subunit. Cell 68:1121-1133. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076. Holmes-McNary M and Baldwin AS, Jr. (2000) Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 60:3477-3483. Hu MC and Hung MC (2005) Role of IkappaB kinase in tumorigenesis. Future Oncol 1:67-78. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R and Hung MC (2004) IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117:225-237. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R and Karin M (1999) Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284:316-320. Huang WC, Chen JJ and Chen CC (2003) c-Src-dependent tyrosine phosphorylation of IKKbeta is involved in tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 expression. J Biol Chem 278:9944-9952. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ and Beach DH (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190:1375-1382. Huxford T, Huang DB, Malek S and Ghosh G (1998) The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 95:759-770. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA and Peyron JF (1996) Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 86:787-798. Jackson LM, Wu KC, Mahida YR, Jenkins D and Hawkey CJ (2000) Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 47:762-770. Jacobs MD and Harrison SC (1998) Structure of an IkappaBalpha/NF-kappaB complex. Cell 95:749-758. Jaiswal M, LaRusso NF, Burgart LJ and Gores GJ (2000) Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60:184-190. Jones NL, Shannon PT, Cutz E, Yeger H and Sherman PM (1997) Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of Helicobacter pylori infection. Am J Pathol 151:1695-1703. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY and Karin M (2000) Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 275:36062-36066. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436. Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663. Karin M, Cao Y, Greten FR and Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310. Karin M and Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759. Karin M and Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3:221-227. Karin M, Yamamoto Y and Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A and Green DR (1998) DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1:543-551. Kato T, Jr., Delhase M, Hoffmann A and Karin M (2003) CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell 12:829-839. Keifer JA, Guttridge DC, Ashburner BP and Baldwin AS, Jr. (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382-22387. King KM and Younes A (2001) Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 1:177-186. Kuper H, Ye W, Broome U, Romelsjo A, Mucci LA, Ekbom A, Adami HO, Trichopoulos D and Nyren O (2001) The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 34:714-718. Kusner DJ (2005) Mechanisms of mycobacterial persistence in tuberculosis. Clin Immunol 114:239-247. Kwok BH, Koh B, Ndubuisi MI, Elofsson M and Crews CM (2001) The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 8:759-766. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ and Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603-607. Leadbetter EA, Rifkin IR and Marshak-Rothstein A (2003) Toll-like receptors and activation of autoreactive B cells. Curr Dir Autoimmun 6:105-122. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC and Anderson KC (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996-5000. Lee JI and Burckart GJ (1998) Nuclear factor kappa B: important transcription factor and therapeutic target. J Clin Pharmacol 38:981-993. Li N and Karin M (1998) Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci U S A 95:13012-13017. Li Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC and Verma IM (1999a) IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 13:1322-1328. Li Q, Van Antwerp D, Mercurio F, Lee KF and Verma IM (1999b) Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284:321-325. Li Q and Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725-734. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R and Karin M (1999c) The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189:1839-1845. Luo JL, Kamata H and Karin M (2005) IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest 115:2625-2632. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Saito M, Kawagoe J, Takahashi K, Yada-Hashimoto N, Sakata M, Motoyama T, Kurachi H, Tasaka K and Murata Y (2004) Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279:23477-23485. Makarov SS (2000) NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 6:441-448. McKay LI and Cidlowski JA (1998) Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 12:45-56. Meyer S, Kohler NG and Joly A (1997) Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett 413:354-358. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD and Chodosh LA (2002) Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2:451-461. Nakanishi C and Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309. Normanno N, Maiello MR and De Luca A (2003) Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 194:13-19. Ogryzko VV, Schiltz RL, Russanova V, Howard BH and Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959. Pereira MA, Grubbs CJ, Barnes LH, Li H, Olson GR, Eto I, Juliana M, Whitaker LM, Kelloff GJ, Steele VE and Lubet RA (1996) Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 17:1305-1311. Peters RT and Maniatis T (2001) A new family of IKK-related kinases may function as I kappa B kinase kinases. Biochim Biophys Acta 1471:M57-62. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S and Howells L (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18:6013-6020. Polat A, Cinel L, Dusmez D, Aydin O and Egilmez R (2002) Expression of cell-cycle related proteins in Helicobacter pylori gastritis and association with gastric carcinoma. Neoplasma 49:95-100. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71-78. Qiao L, Hanif R, Sphicas E, Shiff SJ and Rigas B (1998) Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol 55:53-64. Ranson M (2002) ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist 7 Suppl 4:16-24. Rao CV, Rivenson A, Simi B and Reddy BS (1995) Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55:259-266. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z and Rothe M (1997) Identification and characterization of an IkappaB kinase. Cell 90:373-383. Rice NR and Ernst MK (1993) In vivo control of NF-kappa B activation by I kappa B alpha. Embo J 12:4685-4695. Roder DM (2002) The epidemiology of gastric cancer. Gastric Cancer 5 Suppl 1:5-11. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M and Santoro MG (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403:103-108. Rothwarf DM and Karin M (1999) The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999:RE1. Rothwarf DM, Zandi E, Natoli G and Karin M (1998) IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 395:297-300. Russo SM, Tepper JE, Baldwin AS, Jr., Liu R, Adams J, Elliott P and Cusack JC, Jr. (2001) Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50:183-193. Rusznak C, Mills PR, Devalia JL, Sapsford RJ, Davies RJ and Lozewicz S (2000) Effect of cigarette smoke on the permeability and IL-1beta and sICAM-1 release from cultured human bronchial epithelial cells of never-smokers, smokers, and patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 23:530-536. Savage DG and Antman KH (2002) Imatinib mesylate--a new oral targeted therapy. N Engl J Med 346:683-693. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA and Baldwin AS, Jr. (1995) Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 15:943-953. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC and Karin M (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293:1495-1499. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J and Callery MP (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110-122. Shimada T, Kawai T, Takeda K, Matsumoto M, Inoue J, Tatsumi Y, Kanamaru A and Akira S (1999) IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol 11:1357-1362. Shishodia S and Aggarwal BB (2002) Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol 35:28-40. Sirvent N, Imbert V, Frelin C, Griessinger E and Peyron JF (2003) [Fighting cancer via NF-kappa B inhibition]. Arch Pediatr 10:632-634. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792. Stanciu LA and Djukanovic R (1998) The role of ICAM-1 on T-cells in the pathogenesis of asthma. Eur Respir J 11:949-957. Steeg PS (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3:55-63. Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, Sanjo H, Yoshikawa K, Terada N and Akira S (1999) Limb and skin abnormalities in mice lacking IKKalpha. Science 284:313-316. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M and Lin A (2001) Inhibition of JNK activation through NF-kappaB target genes. Nature 414:313-317. Tergaonkar V, Pando M, Vafa O, Wahl G and Verma I (2002) p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1:493-503. Tsan MF and Gao B (2004) Endogenous ligands of Toll-like receptors. J Leukoc Biol 76:514-519. Turini ME and DuBois RN (2002) Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53:35-57. Ura K, Kurumizaka H, Dimitrov S, Almouzni G and Wolffe AP (1997) Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression. Embo J 16:2096-2107. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S (1995) Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 9:2723-2735. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ and Marshak-Rothstein A (2003) Activation of autoreactive B cells by CpG dsDNA. Immunity 19:837-847. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S and Stewart SJ (2001) First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61 Suppl 2:37-42. Wahl C, Liptay S, Adler G and Schmid RM (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101:1163-1174. Wambura C, Aoyama N, Shirasaka D, Sakai T, Ikemura T, Sakashita M, Maekawa S, Kuroda K, Inoue T, Ebara S, Miyamoto M and Kasuga M (2002) Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis. Helicobacter 7:129-138. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, Coiffier B and Salles G (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91:3574-3581. Weber CK, Liptay S, Wirth T, Adler G and Schmid RM (2000) Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119:1209-1218. Webster GA and Perkins ND (1999) Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 19:3485-3495. Welch DR and Rinker-Schaeffer CW (1999) What defines a useful marker of metastasis in human cancer? J Natl Cancer Inst 91:1351-1353. Woronicz JD, Gao X, Cao Z, Rothe M and Goeddel DV (1997) IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 278:866-869. Xiao G, Cvijic ME, Fong A, Harhaj EW, Uhlik MT, Waterfield M and Sun SC (2001) Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. Embo J 20:6805-6815. Yamamoto Y, Verma UN, Prajapati S, Kwak YT and Gaynor RB (2003) Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 423:655-659. Yamamoto Y, Yin MJ, Lin KM and Gaynor RB (1999) Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274:27307-27314. Yang GF, Deng CS, Xiong YY, Gong LL, Wang BC and Luo J (2004) Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: association with Helicobactor pylori cagA (+) infection. World J Gastroenterol 10:491-496. Yin MJ, Yamamoto Y and Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77-80. Zandi E, Rothwarf DM, Delhase M, Hayakawa M and Karin M (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91:243-252. Zhu W, Downey JS, Gu J, Di Padova F, Gram H and Han J (2000) Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J Immunol 164:6349-6358. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32025 | - |
| dc.description.abstract | Nuclear factor-κB (NF-κB)是innate與adaptive immunity之主要調節分子，IκB kinase (IKK)在NF-κB之活化扮演重要角色，二者均可調控細胞之增生和存活與對抗細胞之凋亡，並維持腫瘤之生成及入侵，是連結發炎反應與腫瘤生成之重要分子。我們之前的研究顯示，TNF-α可經由PKC/c-Src途徑磷酸化IKKβ之Tyr-188與Tyr-199，活化IKKβ而誘發NF-κB之活化，本論文中，我們研究不同IKKβ之磷酸化在腫瘤生成中所扮演的角色，因此我們建立A549/Mock、A549/IKKβ (WT)、A549/IKKβ (AA)與A549/IKKβ (FF)四株stable clones，由體內與體外實驗發現，過度表現IKKβ (WT)可以促進細胞增生、血管新生、入侵與轉移，而IKKβ (AA)與IKKβ (FF)突變株則抑制這些現象，且IKKβ (FF)的抑制效果比IKKβ (AA)來得大，IKKβ (WT)可以降低抑制細胞週期之相關蛋白如p53及p27之表現，因而促進細胞增生，且增加ICAM-1、MMP-2與MMP-9之表現而促進癌細胞之入侵及轉移； IKKβ (AA)與IKKβ (FF)突變株則可增加p53與p27之合成，阻斷ICAM-1、MMP-2與MMP-9生成。這些研究顯示IKKβ的確在癌症生成中扮演非常重要的角色，而tyrosine之磷酸化可能比serine之磷酸化更重要。因此，抑制IKK和NF-κB將是研發化學預防以及化學療法之新策略。 | zh_TW |
| dc.description.abstract | Nuclear factor-κB (NF-κB) is a central coordinator of innate and adaptive immune responses and IκB kinase (IKK) plays an important role in NF-κB activation. Both IKK and NF-κB are critical in linking inflammation and tumorigenesis, which control cell proliferation, survival and anti-apoptosis, and facilitate tumor maintenance and invasion. Our previous studies have shown that PKC/c-Src is involved in the TNF-α-induced NF-κB activation via phosphorylating Tyr-188 and Tyr-199 of IKKβ in A549 alveolar epithelial cells. In this thesis, we attempt to investigate the role of IKKβ in carcinogenesis. Therefore, four stable clones, A549/Mock, A549/IKKβ (WT), A549/IKKβ (AA) and A549/IKKβ (FF) were established. Overexpression of IKKβ (WT) promotes in vivo and in vitro cell proliferation, angiogenesis, invasion and metastasis. However, the dominant-negative IKKβ (AA) and IKKβ (FF) mutant inhibit these effects. The inhibitory effect of IKKβ (FF) is greater than that of IKKβ (AA). IKKβ (WT) can decrease the level of cell cycle associated inhibitory proteins such as p53 and p27 to promote cell proliferation, and increase the protein level of ICAM-1, MMP-2 and MMP-9 to promote cell invasion and metastasis. However, the IKKβ (AA) and IKKβ (FF) mutants increase the synthesis of p53 and p27, and block the production of ICAM-1, MMP-2 and MMP-9. These data suggest that tyrosine is more important than serine phosphorylation, and IKKβ indeed plays an essential role in carcinogenesis. Thus, inhibition of IKK and NF-κB is an attractive target for new chemopreventive and chemotherapeutic approaches. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T03:28:30Z (GMT). No. of bitstreams: 1 ntu-95-R93443011-1.pdf: 4176849 bytes, checksum: ed17d98702c258a11f594483813526ce (MD5) Previous issue date: 2006 | en |
| dc.description.tableofcontents | 目錄
(Contents) 縮寫表……………………………………………………………… 2 (Abbreviation) 中文摘要…………………………………………………………… 5 (Abstract in Chinese) 英文摘要…………………………………………………………… 6 (Abstract in English) 緒論………………………………………………………………… 7 (Introduction) 實驗材料與方法……………………………………………………35 (Materials and Methods) 結果…………………………………………………………………47 (Results) 討論…………………………………………………………………64 (Discussion) 參考文獻……………………………………………………………70 (References) | |
| dc.language.iso | zh-TW | |
| dc.subject | NF-KB | zh_TW |
| dc.subject | 癌症 | zh_TW |
| dc.subject | 發炎反應 | zh_TW |
| dc.subject | IKKb | zh_TW |
| dc.subject | IKKb | en |
| dc.subject | NF-KB | en |
| dc.subject | cancer | en |
| dc.subject | inflammation | en |
| dc.title | IKKb在癌症生成角色之研究 | zh_TW |
| dc.title | The Role of IKKb in Carcinogenesis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 楊春茂(Chuen-Mao Yang),吳明賢(Ming-Shiang Wu) | |
| dc.subject.keyword | IKKb,NF-KB,癌症,發炎反應, | zh_TW |
| dc.subject.keyword | IKKb,NF-KB,cancer,inflammation, | en |
| dc.relation.page | 80 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2006-07-28 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-95-1.pdf 未授權公開取用 | 4.08 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。